Cos'è il teplizumab?

Teplizumab is the UK’s first-ever approved medicine that can be used treat type 1 diabetes using immunotherapy - which activates or suppresses the body’s immune system. Teplizumab has been approved for by MHRA for people with Stage 2 T1D, which is an earlier stage where people are at high risk of progressing to Stage 3 T1D.

The medicine can delay the onset of Stage 3 T1D by an average of three years in adults and children aged 8 years and older, who already have Stage 2 T1D.

Teplizumab viene somministrato direttamente nel flusso sanguigno (infusione endovenosa), di solito tramite una flebo, una volta al giorno, per 14 giorni.

La dottoressa Elizabeth Robertson, Direttrice della Ricerca e Clinica di Diabetes UK, afferma: “L'autorizzazione di teplizumab nel Regno Unito segna un punto di svolta nel trattamento del diabete di tipo 1. Per la prima volta, abbiamo un farmaco che mira alla causa principale della condizione, offrendo fino a tre preziosi anni in più rispetto alle incessanti esigenze di gestire il diabete di tipo 1.”

Quando viene diagnosticato il T1D di Stadio 3?

You are usually diagnosed with Stage 3 T1D when you begin to have blood sugar problems which often require lifelong insulin treatment.

Teplizumab has been approved through the International Recognition Procedure (IRP), whose expertise the MHRA can use to benefit people in the UK. A full list of side effects will be published before teplizumab sia reso disponibile.

As with any medicine, the MHRA will keep monitoring the safety and effectiveness of teplizumab.

If you think you are having a side effect from this medicine speak to your doctor, pharmacist, or nurse. You should also report it directly to the Schema della Scheda Gialla MHRA.